1. Andronate
2. Depo-testosterone
3. Depo-testosterone Cypionate
4. Deposteron
5. Depostomead
6. Duratest
7. Testa-c
8. Testex Elmu
9. Testosterone 17 Beta-cyclopentanepropionate
10. Testosterone 17 Beta-cyclopentylpropionate
11. Testosterone 17 Beta-cypionate
1. 58-20-8
2. Depo-testosterone
3. Depovirin
4. Jectatest
5. Testosterone Cyclopentylpropionate
6. Testosterone Cyclopentanepropionate
7. Pertestis
8. Testosterone 17beta-cypionate
9. Andro-cyp
10. Dep-test
11. Malogen Cyp
12. Depandro 100
13. Depandro 200
14. T-ionate-p.a
15. Testodrin Prolongatum
16. Testosterone Cipionate
17. Depo-testadiol
18. Durandro
19. Nsc 9157
20. Testosterone Cypionate Ciii
21. M0xw1ubi14
22. Testosterone 17beta-cyclopentylpropionate
23. Testosterone Cypionate [usp]
24. Chebi:9463
25. Testosterone 17.beta.-cyclopentanepropionate
26. Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-
27. Testosterone, Cyclopentanepropionate
28. Nsc-9157
29. Testosterone 17beta-cyclopentanepropionate
30. Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17.beta.)-
31. Depo-testosterone Cypionate
32. [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
33. Testosterone Cypionate (usp)
34. 17-(3-cyclopentyl-1-propionyl)-17beta-hydroxyandrost-4-en-3-one
35. Unii-m0xw1ubi14
36. Testosterone 17.beta.-cypionate
37. Depotest
38. Testosterone 17-beta-cypionate
39. (8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl 3-cyclopentylpropanoate
40. Einecs 200-368-4
41. Testosterone 17.beta.-cyclopentylpropionate
42. Depo-testosterone Cyclopentylpropionate
43. Brn 3174363
44. Depo-testosterone (tn)
45. Schembl40862
46. 17beta-hydroxyandrost-4-en-3-one Cyclopentylpropionate
47. Chembl1201101
48. Dtxsid901015617
49. Zinc4097468
50. Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17beta)-
51. Lmst02020074
52. Testosterone Cypionate [vandf]
53. Akos007930349
54. Akos015895326
55. Testosterone Cipionate [mart.]
56. Db13943
57. Ds-3318
58. Testosterone Cipionate [who-dd]
59. Testosterone Cypionate [orange Book]
60. Testosterone Cypionate Ciii [usp-rs]
61. Testosterone Cypionate [usp Monograph]
62. C08156
63. D00957
64. Ab01274709-01
65. 053t944
66. W-105407
67. 3-oxoandrost-4-en-17beta-yl 3-cyclopentylpropanoate
68. Depo-testadiol Component Testosterone Cypionate
69. Q27108401
70. Testosterone Cypionate 100 Microg/ml In Acetonitrile
71. Testosterone Cypionate Component Of Depo-testadiol
72. (17beta)-3-oxoandrost-4-en-17-yl 3-cyclopentylpropanoate
73. 17.beta.-hydroxyandrost-4-en-3-one Cyclopentylpropionate
74. Testosterone 17.beta.-cyclopentanepropionate [mi]
75. 17-(cyclopentyl-1-oxopropoxy)androst-4-en-3-one, (17.beta.)-
76. 3-oxoandrost-4-en-17-yl 3-cyclopentylpropanoate, (17.beta.)- #
77. Testosterone Cypionate, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 412.6 g/mol |
|---|---|
| Molecular Formula | C27H40O3 |
| XLogP3 | 6.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 412.29774513 g/mol |
| Monoisotopic Mass | 412.29774513 g/mol |
| Topological Polar Surface Area | 43.4 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 732 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.
FDA Label
Administration of ester derivatives of testosterone as testosterone cypionate generates an increase in serum testosterone to levels reaching 400% from the baseline within 24 hours of administration. These androgen levels remain elevated for 3-5 days after initial administration. The continuous variation in plasma testosterone after intramuscular administration of testosterone cypionate results in fluctuations in mood and libido as well as some local inflammation.
Androgens
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)
Anabolic Agents
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)
Absorption
Testosterone cypionate is an esterified anabolic which allows it to present a greater degree of solubility in fats and thus, the release and absorption occur in a slow rate compare to homologous molecules. Intramuscular administration of 200 mg of testosterone cypionate produced a mean supratherapeutic Cmax of 1122 ng/dl which occurred 4-5 days post-injection. After the fifth day, the levels of testosterone cypionate in plasma went down reaching an average of 400 ng/dl.
Route of Elimination
About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form.
Volume of Distribution
The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.
Clearance
Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.
To start its activity, testosterone cypionate has to be processed by enzymes in the bloodstream. These enzymes will break the bond between the cypionate ester moiety and the testosterone. Once separated, testosterone is metabolized to 17-keto steroids through two different pathways. The major active metabolites are estradiol and dihydrotestosterone (DHT). Testosterone is metabolized to DHT by steroid 5-reductase in skin, liver and urogenital tract. In reproductive tissues DHT is further metabolized to androstanediol.
The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.
The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5-alpha-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5-alpha-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
LOOKING FOR A SUPPLIER?
